{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:44:46Z","timestamp":1792604686204,"version":"4.5.0"},"reference-count":18,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2004,7,21]],"date-time":"2004-07-21T00:00:00Z","timestamp":1090368000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2004,8]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background<\/jats:bold> :\u2002Patients with refractory gastro\u2010oesophageal reflux disease, extra\u2010oesophageal reflux symptoms, Barrett's oesophagus, or Zollinger\u2013Ellison syndrome may require greater acid suppression than that obtained with once\u2010daily esomeprazole.<\/jats:p><jats:p><jats:bold>Aim<\/jats:bold> :\u2002To assess gastric acid suppression (determined by intragastric pH) and pharmacokinetics of twice\u2010daily vs. once\u2010daily esomeprazole.<\/jats:p><jats:p><jats:bold>Methods<\/jats:bold> :\u2002In a randomized, double\u2010blind, three\u2010way crossover study, healthy subjects received esomeprazole 40\u2003mg once daily, 20\u2003mg twice daily, or 40\u2003mg twice daily for five consecutive days. Twenty\u2010four\u2010hour continuous ambulatory intragastric pH was recorded on day 5.<\/jats:p><jats:p><jats:bold>Results<\/jats:bold> :\u2002Esomeprazole 40\u2003mg twice daily provided a mean of 19.2\u2003h with intragastric pH\u2003&gt;\u20034.0 (80.1% of a 24\u2010h time period; 95% confidence interval 74.5\u201385.7%) vs. 14.2\u2003h with 40\u2003mg once daily (59.2%; 95% CI 53.7\u201364.7%) and 17.5\u2003h with 20\u2003mg twice daily (73.0%; 95% confidence interval 67.4\u201378.5%) in 25 subjects. Intragastric pH was maintained &gt;4.0 for a similar percentage of time during active and sleeping periods for all doses.<\/jats:p><jats:p><jats:bold>Conclusions<\/jats:bold> :\u2002Esomeprazole 40\u2003mg twice daily provides significantly greater acid suppression (number of hours in a 24\u2010h period with pH\u2003&gt;\u20034.0) than once\u2010daily dosing and may be a reasonable consideration for patients requiring greater acid suppression for acid\u2010related disease.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2004.02079.x","type":"journal-article","created":{"date-parts":[[2004,8,5]],"date-time":"2004-08-05T15:23:16Z","timestamp":1091719396000},"page":"399-406","source":"Crossref","is-referenced-by-count":61,"title":["Intragastric acid suppression and pharmacokinetics of twice\u2010daily esomeprazole: a randomized, three\u2010way crossover study"],"prefix":"10.1111","volume":"20","author":[{"given":"P. O.","family":"Katz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. O.","family":"Castell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. B.","family":"Sostek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,7,21]]},"reference":[{"key":"e_1_2_16_2_2","doi-asserted-by":"publisher","DOI":"10.1159\/000200917"},{"key":"e_1_2_16_3_2","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/j.1572-0241.1999.1123_a.x","article-title":"Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology","volume":"94","author":"DeVault KR","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_16_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00813.x"},{"key":"e_1_2_16_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.08783.x"},{"key":"e_1_2_16_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(08)82079-3"},{"key":"e_1_2_16_7_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1015009300955"},{"key":"e_1_2_16_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005537-200304000-00003"},{"key":"e_1_2_16_9_2","unstructured":"Nexium [full prescribing information].Wilmington DE:AstraZenecaLP;2004. Available athttp:\/\/www.astrazeneca\u2010vs.com\/pi\/Nexium.pdf.Accessed 22 June 2004."},{"key":"e_1_2_16_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-002-0502-1"},{"key":"e_1_2_16_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2002.01168.x"},{"key":"e_1_2_16_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1998.00418.x"},{"key":"e_1_2_16_13_2","first-page":"1532","article-title":"Optimal dosing of omeprazole 40\u2003mg daily: effects on gastric and esophageal pH and serum gastrin in healthy controls","volume":"91","author":"Kuo B","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_16_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1998.00426.x"},{"key":"e_1_2_16_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.05532.x"},{"key":"e_1_2_16_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00856.x"},{"key":"e_1_2_16_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01464.x"},{"key":"e_1_2_16_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.03600.x"},{"key":"e_1_2_16_19_2","unstructured":"LabenzJon behalf of the EXPO study group KeelingNEklundS.A comparison of esomeprazole 40\u2003mg once\u2010daily and pantoprazole 40\u2003mg once\u2010daily for the healing of erosive esophagitis. Abstract submitted to Canadian Digestive Diseases Week; Banff Alberta; February 27\u2013March 1 2004."}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2004.02079.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2004.02079.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2004.02079.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T21:22:46Z","timestamp":1697232166000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2004.02079.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7,21]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,8]]}},"alternative-id":["10.1111\/j.1365-2036.2004.02079.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2004.02079.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,7,21]]}}}